Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Daptomycin-Oxacillin Combinations in Treatment of Experimental Endocarditis Caused by Daptomycin-Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus with Evolving Oxacillin Susceptibility (the “Seesaw Effect”)

Soo-Jin Yang, Yan Q. Xiong, Susan Boyle-Vavra, Robert Daum, Tiffanny Jones, Arnold S. Bayer
Soo-Jin Yang
1Los Angeles Biomedical Research Institute, Torrance, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sjyang@labiomed.org
Yan Q. Xiong
1Los Angeles Biomedical Research Institute, Torrance, California
2David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Boyle-Vavra
3Department of Pediatrics, University of Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Daum
3Department of Pediatrics, University of Chicago, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiffanny Jones
1Los Angeles Biomedical Research Institute, Torrance, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnold S. Bayer
1Los Angeles Biomedical Research Institute, Torrance, California
2David Geffen School of Medicine, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00487-10
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Population analyses of study strains upon exposure to a range of DAP (left panel) or OX (right panel) concentrations. These data represent the means (± SD) for two separate assays. conc., concentration.

    • Open in new tab
    • Download powerpoint
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    OX time-kill analyses. Six DAPs and DAPr strain pairs were used for these experiments. (A) CB1118-CB2205; (B) MRSA 11/11-REF2145; (C) CB1482-CB184; (D) BMC1001-BMC1002; (E) CB5053-CB5054; (F) CB5035-CB5036. Time-kill experiments were performed using Mueller-Hinton broth with a 106-CFU/ml inoculum in the presence of 0 to 256 μg/ml OX.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    In vitro synergy kill curves for DAPr REF2145 (A) and CB5054 (B) strains. These two strain sets were used in the experimental IE studies detailed in the text. The growth curve for the no-antibiotic growth control for these experiments is not shown but was identical to the growth curve for both strains with one-quarter of the MIC of DAP.

Tables

  • Figures
  • TABLE 1.

    Strains used in this study

    Strain (pulsotype)aSCCmec typeDescriptionMIC (μg/ml)Reference(s)
    DAPOX
    CB1118 (USA400)IVSelected in vitro by serial passage in DAP0.524 15, 29
    CB2205 (USA400)IVSelected in vitro by serial passage in DAP86
    MRSA 11/11 (USA300)*IVClinical endocarditis isolate0.3832 31
    REF2145 (USA300)*IVClinical endocarditis isolate46
    CB1482 (USA500)IVClinical bloodstream isolate0.564 15
    CB184 (USA500)IVClinical bloodstream isolate216
    BMC1001 (USA500)IVClinical bloodstream isolate0.5>256This study
    BMC1002 (USA500)IVClinical bloodstream isolate2128
    CB5053 (USA100)*IIClinical bloodstream isolate0.564This study
    CB5054 (USA100)*IIClinical bloodstream isolate224
    CB5035 (USA100)IIClinical bloodstream isolate0.38192This study
    CB5036 (USA100)IIClinical bloodstream isolate296
    • ↵ a *, strain used in the in vivo endocarditis studies.

  • TABLE 2.

    MRSA 11/11-REF2145 and CB5053-CB5054 counts in target tissues with DAP and/or OX treatment in the IE model

    Group (no. of animals)aS. aureus density (log10 CFU/g tissue) inb:
    VegetationKidneySpleen
    Control without treatment
        MRSA 11/11 (8)7.74 ± 0.795.51 ± 0.635.28 ± 0.56
        MRSA REF2145 (8)8.84 ± 0.566.29 ± 0.676.15 ± 0.65
        CB5053 (6)7.74 ± 0.805.98 ± 0.985.84 ± 0.53
        CB5054 (6)8.76 ± 0.186.63 ± 0.755.95 ± 0.65
    Treatment
        MRSA 11/11 (12 mg/kg DAP i.v. once daily) (7)1.58 ± 0.590.53 ± 0.280.60 ± 0.16
        MRSA REF2145 (12 mg/kg DAP i.v. once daily) (7)7.93 ± 1.12*6.74 ± 0.71*5.52 ± 1.23*
        MRSA 11/11 (200 mg/kg OX i.m. t.i.d.) (8)5.96 ± 2.233.99 ± 1.434.07 ± 1.17
        MRSA REF2145 (200 mg/kg OX i.m. t.i.d.) (8)7.21 ± 1.395.09 ± 1.994.79 ± 1.51
        MRSA REF2145 (DAP-OX) (8)4.20 ± 1.61**2.90 ± 1.50**3.12 ± 0.81**
        CB5053 (12 mg/kg DAP i.v. once daily) (6)1.71 ± 0.960.95 ± 0.601.07 ± 0.92
        CB5054 (12 mg/kg DAP i.v. once daily) (6)8.34 ± 0.83*6.32 ± 1.31*5.78 ± 1.29*
        CB5053 (200 mg/kg OX i.m. t.i.d.) (7)6.18 ± 1.744.01 ± 1.823.88 ± 1.19
        CB5054 (200 mg/kg OX i.m. t.i.d.) (6)8.96 ± 0.446.35 ± 1.025.68 ± 0.80
        CB5054 (DAP-OX) (10)5.70 ± 1.98**3.88 ± 1.25**3.99 ± 0.95**
    • ↵ a 12 mg/kg DAP intravenously (i.v.) once daily is equivalent to a dose of 6 mg/kg once daily in humans (7).

    • ↵ b *, P value of <0.001 relative to the value for DAPs MRSA 11/11 or CB5053 with DAP treatment; **, P value of <0.05 relative to the value for REF2145 or CB5054 with OX-only or DAP-only treatment.

PreviousNext
Back to top
Download PDF
Citation Tools
Daptomycin-Oxacillin Combinations in Treatment of Experimental Endocarditis Caused by Daptomycin-Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus with Evolving Oxacillin Susceptibility (the “Seesaw Effect”)
Soo-Jin Yang, Yan Q. Xiong, Susan Boyle-Vavra, Robert Daum, Tiffanny Jones, Arnold S. Bayer
Antimicrobial Agents and Chemotherapy Jul 2010, 54 (8) 3161-3169; DOI: 10.1128/AAC.00487-10

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Daptomycin-Oxacillin Combinations in Treatment of Experimental Endocarditis Caused by Daptomycin-Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus with Evolving Oxacillin Susceptibility (the “Seesaw Effect”)
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Daptomycin-Oxacillin Combinations in Treatment of Experimental Endocarditis Caused by Daptomycin-Nonsusceptible Strains of Methicillin-Resistant Staphylococcus aureus with Evolving Oxacillin Susceptibility (the “Seesaw Effect”)
Soo-Jin Yang, Yan Q. Xiong, Susan Boyle-Vavra, Robert Daum, Tiffanny Jones, Arnold S. Bayer
Antimicrobial Agents and Chemotherapy Jul 2010, 54 (8) 3161-3169; DOI: 10.1128/AAC.00487-10
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
daptomycin
Disease Models, Animal
Drug Resistance, Bacterial
Endocarditis, Bacterial
methicillin-resistant Staphylococcus aureus
oxacillin

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596